Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology

Arthritis medications
newGeneral Health
Medicinal food
Chinese medicine
OTC Drugs
Health Products


Each capsule contains Orlistat 120mg.

Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides.

The extent of absorption of orlistat was minimal. Plasma concentrations of intact orlistat were non-measurable (< 5 ng/ml) following a single oral administration 360mg of orlistat. In general, after long term treatment at therapeutic doses, detection of intact orlistat in plasma was sporadic and concentrations were extremely low (< 10 ng/ml or 0.02 Ámol), with no evidence of accumulation, which is consistent with minimal absorption.

The volume of distribution cannot be determined because the drugs minimally absorbed and has no defined systemic pharmacokinetics. In vitro orlistat is > 99 % bound to plasma proteins (lipoproteins and albumin were the major binding proteins). Orlistat minimally partitions into erythrocytes.

Two major metabolites, M1 (4-member lactone ring hydrolysed) and M3 (M1 with N-formyl leucine moiety cleaved), accounted for approximately 42% of the total plasma concentration.

M1 and M3 have an open beta-lactone ring and extremely weak lipase inhibitory activity (1000 and 2500 fold less than orlistat respectively). In view of this low inhibitory activity and the low plasma levels at therapeutic doses (average of 26 ng/ml and 108 ng/ml respectively), these metabolites are considered to be pharmacologically inconsequential.

Faecal excretion of the unabsorbed drug was the major route of elimination. Approximately 97% of the administered dose was excreted in faeces and 83 % of that as unchanged orlistat.

The cumulative renal excretion of total orlistat-related materials was < 2% of the given dose, The time to reach complete excretion (faecal plus urinary) was 3 to 5 days. The disposition of orlistat appeared to be similar between normal weight and obese volunteers. Orlistat, Ml and M3 are all subject to biliary excretion.

Phormacokinetics in Special Populations
Plasma concentrations of orlistat and its metabolites Ml and M3 were similar in paediatric patients compared to those found in adults at the same dose level. Daily fecal fat excretions were 27% and 7% of dietary intake in orlistat and placebo treatment groups, respectively.

Aslene is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI ≥ 28 kg/m2) with risk factors associated with obesity.

Aslene is effective in weight loss, weight maintenance and prevention of weight regains. Treatment with Aslene results in an improvement of risk factors and comorbidities associated with obesity, including hypercholesterolemia, noninsulin dependent diabetes mellitus (NIDDM), impaired glucose tolerance, hyperinsulinemia, hypertension and in a reduction of visceral fat.

The use of Aslene in type 2 diabetic patients who are overweight (BMI ≥ 28 kg/m2) or obese (BMI ≥ 30 kg/m2), in conjunction with a mildly hypocaloric diet, provides additional glycemic control when used in combination with antidiabetic agents such as metformin, sulfonylurea and/or insulin.

Treatment with Aslene should only be started if diet alone has previously produced a weight loss of at least 2.5kg over a period of 4 consecutive weeks. Treatment with Aslene should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.


The recommended dose of Aslene is one 120mg capsule with each main meal (during or up to one hour after the meal). If a meal is missed or contains no fat, the dose of Aslene may be omitted.

The patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately 30% of calories from fat. The daily intake of fat, carbohydrate and protein should be distributed over three main meals.

Doses above 120 mg three times daily have not been shown to provide additional benefit.

Special populations
The effect of orlistat in patients with hepatic and/or renal impairment, children under the age of 12, and elderly patents has not been studied.

Aslene is contraindicated in patients with chronic malabsorption syndrome, cholestasis and in patients with known hypersensitivity to orlistat or any component of this product.

In order to ensure adequate nutrition, the use of a multivitamin supplement (Vitamin A, D, E and K, and beta-carotene) should be considered.

Patients should be advised to adhere to dietary guidelines (see Dosage and Administration).

A reduction in cyclosporin plasma levels has been observed when orlistat is co-administered. Therefore it is recommended to monitor more frequently than usual the cyclosporin plasma levels when orlistat is co-administered.

A potential reduced therapeutic effect of amiodarone is possible due to the complex pharmacokinetics of amiodarone.

The possibility of experiencing gastrointestinal adverse reactions (see Side Effects) may increase when orlistat is taken with a diet high in fat (e.g. in a 2000 kcal/day diet, >30% of calories from fat equates to >67g of fat). The daily intake of fat should be distributed over three main meals. If orlistat is taken with any one meal very high in fat, the possibility of gastrointestinal effects may increase.

Weight loss induced by orlistat is accompanied by improved metabolic control in type 2 diabetics which might allow or require reduction in the dose of oral hypoglycemic medication (eg. sulfonylureas).

Substantial weight loss may increase the risk of cholelithiasis.

Coagulation parameters should be monitored in patients treated with concomitant oral anticoagulants.

Cases of rectal bleeding have been reported with orlistat. Presenters should investigate further in case of severe and/or persistent symptoms.


1    2











Health news
Cardiovascular Guide
Natural Remedies
Treatment of Cancer
Women's Health
Irritable bowel syndrome
Common Childhood Illnesses
Prescribed Drugs